Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-blockers with or without umeclidinium + vilanterol in COPD
ACTRN12621001503819Phase 4Not yet recruiting
- Sponsor
- Waikato District Health Board
- Start
- Dec 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of carvedilol, bisoprolol and Anoro Ellipta in chronic obstructive pulmonary disease (COPD) and cardiac morbidity (6 arms), sponsored by Waikato District Health Board. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
carvedilolbisoprololAnoro Ellipta
03
Conditions
chronic obstructive pulmonary disease (COPD)cardiac morbidity
Beyond the preview
Go deeper on ACTRN12621001503819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001503819.